SATEN III—Splitting Adjuvant Treatment of stage III ENdometrial cancers: an international, multicenter study

What is it about?

Despite the development in adjuvant treatment modalities, survival of patients with stage III endometrial cancer patients remains the same for more than 30 years. 
All available randomized clinical trials on stage III endometrial cancer have put women with any histological subtype and any sub-stage into the same cluster. Considering all sub-stages together in the same class and applying the same adjuvant treatment modality may cause over- or under-treatment. 
To date, this is the largest retrospective study on stage III endometrioid endometrial cancer. With the present study, our data show whether or not adjuvant treatment of stage III endometrioid endometrial cancer should differ according to the subgroups.

Featured Image